NBB - I would be one of the some you refer to. My understanding is that management gets a data read-out every week on all of the patients that are currently being dosed in this trial. The trial is unblinded so in theory any company that may be interested in pursuing ZEN-3694 could have one of their Dr's stand right beside a clinical Dr administering the drug or doing testing with a patient as it is happening. For that matter the investment bankers from either side of a deal could be there as well. 

IMO the fact that management does not have to say anything to the market gives them a significant advantage in negotiations over a public company that must report trial results within certain time constraints.

tada